Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Medical treatment for recurrent miscarriages].

Joëlle Belaisch-Allart1, J M Mayenga

  • 1Service de gynécologie-obstétrique, CHI Jean-Rostand, 141, Grande Rue, 92311 Sèvres, France. joelle.belaisch-allart@libertysurf.fr

Gynecologie, Obstetrique & Fertilite
|July 31, 2002
PubMed
Summary

Few effective treatments exist for recurrent pregnancy loss. While aspirin, prednisone, and heparin are common, their efficacy over expectant management is unproven, except for antiphospholipid syndrome. Progesterone is low-risk but its effectiveness is not established.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[National fertility plan 2026: Break the taboo, take action].

Gynecologie, obstetrique, fertilite & senologie·2026
Same author

[Surrogacy: Is FIGO's position acceptable in France?]

Gynecologie, obstetrique, fertilite & senologie·2026
Same author

[The French College of Gynecologists and Obstetricians is very concerned about the moratorium on maternity unit closures voted through the French National Assembly].

Gynecologie, obstetrique, fertilite & senologie·2025
Same author

[First-line management of infertile couple. Guidelines for clinical practice of the French College of Obstetricians and Gynecologists 2022].

Gynecologie, obstetrique, fertilite & senologie·2024
Same author

[Doctor-patient relations: how did we arrive at the current climate, and what can be done about it?]

La Revue du praticien·2023
Same author

[Bioethics law and MAP: unacceptable delays].

La Revue du praticien·2023

Area of Science:

  • Reproductive Medicine
  • Obstetrics and Gynecology
  • Clinical Therapeutics

Context:

  • Recurrent pregnancy loss (RPL) presents a significant challenge in reproductive medicine.
  • Current therapeutic options for RPL lack robust evidence of efficacy.
  • Established treatments often fail to demonstrate superiority over watchful waiting.

Purpose:

  • To evaluate the evidence supporting common therapies for recurrent pregnancy loss.
  • To assess the efficacy of aspirin, prednisone, heparin, and progesterone supplementation.
  • To guide clinical decision-making based on proven benefits and potential harms.

Summary:

  • Aspirin, prednisone, and heparin are frequently used for RPL but are not definitively proven effective compared to expectant management.

Related Experiment Videos

  • These interventions show benefit primarily in cases of antiphospholipid syndrome.
  • Progesterone supplementation, while low-risk, remains unproven in its effectiveness for RPL.

    • Impact:

    • Highlights the limited evidence for common RPL treatments, emphasizing the need for further research.
    • Underscores the importance of individualized treatment guided by specific diagnoses like antiphospholipid syndrome.
    • Promotes a cautious approach, prioritizing patient safety and the principle of "do no harm" in managing recurrent pregnancy loss.